Important Trials Show Improved Survival in Metastatic Breast Cancer: Day 4 of the European Society for Medical Oncology’s 2021 Congress

Important Trials Show Improved Survival in Metastatic Breast Cancer: Day 4 of the European Society for Medical Oncology’s 2021 Congress

Main
Two phase 3 trials found that women with metastatic breast cancer survived longer when given combination therapy including standard care and an additional drug, according to the results of late-breaking studies presented at the annual meeting of the European Society for Medical Oncology (ESMO). The MONALEESA-2 trial found that adding Kisqali (ribocliclib), a category of drug known as a CDK4/6 inhibitor, to hormonal treatment extended survival for women with hormone receptor-positive (HR-positive), HER2-negative advanced breast cancer. Similarly, results from the KEYNOTE-355 trial showed increased survival for women whose metastatic triple-negative breast cancer (TNBC) expressed a biomarker known as PD-L1.MONALEESA-2: Kisqali Plus Standard Hormone Therapy Extends Survival by One Year in Metastatic HR-Positive/HER2-Negative Breast CancerWhat’s New Postmenopausal women with HR-positive, HER2-negative advanced breast cancer who received Kisqali in addition to the standard…
Read More